LKFT
BuyFallen FavouriteFLAGLakefront Biotherapeutics NV · Healthcare · Belgium · $1.9B · Avg Vol: $8M/d
Fallen Favourite: A good business that is expensive and falling. Wait for the price to catch up.
Insufficient evidence for a screen-pass. Lakefront Biotherapeutics NV: fails the quant gate on value, momentum (Q71/V48/M41; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT LAKEFRONT BIOTHERAPEUTICS NV
Read
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 277.2M | 275.4M | 316.7M | 1.3B | 66.4% | 1.1B |
| EPS | -3.81 | 3.69 | 1.29 | 5.60 | 23.2% | 10.41 |
| Shares | 65.8M | 65.9M | 65.9M | 65.9M | +0.1% | 65.5M |
| Debt | 25.2M | 11.0M | 13.5M | 7.9M | -31.9% | 7.3M |
| Equity | 2.9B | 3.2B | 3.3B | 3.7B | 8.6% | — |
| Op CF | -575.1M | -466.5M | -367.7M | -295.8M | — | -260.5M |
| Inv CF | -1.4B | 81.8M | 253.5M | 331.9M | — | — |
| Fin CF | -1.7M | -5.7M | -5.7M | -3.8M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LKFT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LKFT | Lakefront Biotherapeutics NV(you) | $1.9B | 68 | Buy |
| TUB.BR | Financière de Tubize SA | $9.6B | 29 | Sell |
| AGMB | AgomAb Therapeutics NV | $649M | 14 | Strong Sell |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
| HYL.BR | Hyloris Pharmaceuticals SA | $143M | 14 | Strong Sell |
| FAGR.BR | Fagron NV | $1.9B | 83 | Strong Buy |
| IBAB.BR | Ion Beam Applications SA | $567M | 71 | Buy |
| NYXH | Nyxoah SA | $163M | 10 | Strong Sell |
| MDXH | MDxHealth SA | $69M | 13 | Strong Sell |
| SEQUA.BR | Sequana Medical NV | $54M | 13 | Strong Sell |
Peer medians: ROE -8.3% · P/E 18.6x · Gross margin 60.2%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.